3 ASX healthcare shares to buy for strong long-term growth

Here we look at Cochlear Limited (ASX: COH) and 2 other ASX 200 healthcare shares to consider buying for their strong long-term growth potential.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

I am particularly interested in the ASX healthcare sector due to the growing number of high-quality companies that are now listed, many of which have seen strong share price growth over the past 5 years.

In addition, I believe the demand for healthcare services is only going to grow over the next decade due to an ageing global population and continuing advances in healthcare treatments and technology.

With that in mind, here are 3 of my top picks in the ASX healthcare space right now:

Ramsay Health Care Limited (ASX: RHC)

Over the past decade, global private hospital provider Ramsay has experienced strong revenue growth from its existing facilities, as well as growing through acquisitions and expanding into new markets. It has now achieved considerable size and scale, which therefore spreads its operating costs and provides it with a distinct competitive advantage in negotiations with health insurers.

Ramsay has been impacted by the ban on non-essential surgeries across the countries in which it operates. However, with elective surgeries beginning to recommence in Australia, and with other markets likely to soon follow, it may merge from its troubles faster than anticipated.

As one of the largest hospital providers in the world, with operations across 11 countries, I believe that Ramsay is well-positioned to capitalise on the growing need for healthcare services over the next decade.

Cochlear Limited (ASX: COH)

Cochlear has been significantly impacted by the coronavirus crisis as elective surgeries, such as those for cochlear implants, have been deferred across a number of countries in which it operates. This led to Cochlear raising $880 million from an institutional placement in late March.

However, with the Cochlear share price taking a significant hit over the past few months, and the hope that elective surgeries may soon commence across a number of its markets, I believe now could be a good buying opportunity.

As the proportion of the global population over the age of 65 continues to increase, I think the demand for hearing products and solutions over the next few decades will only rise.

ResMed Inc (ASX: RMD)

ResMed has evolved over the last 30 years to become one of the world's leading sleep treatment companies. It is now a major US-based global company, employing more than 7,00 people worldwide.

The company's healthcare devices and cloud-based software solutions target sleep apnea and other respiratory conditions. Its global scale and breadth now provide it with a distinct advantage over its competitors. The company recently recorded an impressive 47% increase in net income during the third quarter of FY 2020.

I believe that the strong demand for ResMed's products is likely to continue over the next decade, driven by the largely untapped market of sleep apnea sufferers globally.

Phil Harpur owns shares of Cochlear Ltd. and ResMed Inc. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd., Ramsay Health Care Limited, and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Guess which ASX 200 stock just jumped 9% on big news

Let's find out what is getting investors excited today.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

What are Cochlear shares worth according to Macquarie?

Let's see what the broker is saying about this blue chip.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

When will CSL shares finally catch a break?

Here's where analysts think the biotech stock is heading next.

Read more »

An analyst wearing a dark blue shirt and glasses sits at his computer with his chin resting on his hands as he looks at the CBA share price movement today
Healthcare Shares

JP Morgan initiates coverage of Telix Pharmaceuticals. After rising 1,667% in 5 years, is it still a buy?

Can this ASX 200 juggernaut go higher?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why this top broker expects CSL shares to surge 26%

A leading broker foresees a big rebound ahead for CSL shares. But why?

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

Guess which ASX All Ords stock is jumping on big US news

This small cap is catching the eye on Thursday. But why?

Read more »

three excited doctors with hands in the air
Healthcare Shares

Two ASX healthcare shares that could be set to double

This broker has buy recommendations on these two shares. 

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Telix shares jump 7% on big US news

Let's see what is getting investors excited on Wednesday.

Read more »